227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
February 2023 in “Journal of The American Academy of Dermatology” This publication discusses the use of low-dose oral minoxidil for treating traction alopecia but reports no new clinical outcomes; further research on its efficacy and safety is needed.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.
14 citations
,
September 2020 in “Dermatologic Therapy” This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.
49 citations
,
February 2019 in “The Journal of Clinical Endocrinology and Metabolism” This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.
56 citations
,
October 2018 in “Journal of The American Academy of Dermatology” This review discusses the role of androgens in women's skin-related conditions like acne, hirsutism, and female pattern hair loss, noting the lack of dermatology guidelines for when to pursue endocrinologic evaluation.
40 citations
,
September 2017 in “F1000Research” In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.
43 citations
,
April 2017 in “Experimental Dermatology” This review summarizes the genetic studies on female pattern hair loss, highlighting the lack of clearly identified susceptibility loci and suggesting distinct aetiological differences from male pattern hair loss.
55 citations
,
July 2016 in “Dermatologic Therapy” This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.
8 citations
,
October 2015 in “PubMed” Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.
87 citations
,
May 2012 in “PLOS Genetics” This study found that early-onset androgenetic alopecia in individuals of European ancestry is significantly associated with increased odds of Parkinson's disease and is influenced by specific genetic loci, including some linked to reduced fertility.
9 citations
,
September 2010 in “Dermatologic Therapy” This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
155 citations
,
December 2003 in “British Journal of Dermatology” In this study, the researchers did not confirm previously reported links between AGA and smoking or benign prostatic hypertrophy, but found potential associations with alcohol consumption and lean body mass at age 21 that merit further investigation.
149 citations
,
June 2002 in “British Journal of Dermatology” Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.
131 citations
,
August 2000 in “International Journal of Dermatology” Inflammation may be linked to hair loss, and targeting specific enzymes could help treat it.
